Irish Eyes May Smile On Taxes, But Medtronic Says There’s More To Covidien Deal
This article was originally published in The Gray Sheet
The $42.9 billion Medtronic-Covidien deal is the largest pure medical device deal ever. It would move Medtronic’s corporate address to Ireland, with a lower tax rate, but executives emphasize negotiating power with hospitals, product synergies and emerging-market footprint, as well as new flexibility to use overseas cash, as core rationales for the deal.
You may also be interested in...
Medtronic CEO Omar Ishrak Announces Retirement; Geoff Martha Will Be New CEO
Ishrak will remain with the company as executive chairman. Geoff Martha, the current head of Medtronic’s restorative therapies group, will become president on 1 November and CEO in April 2020. Brett Wall, the current lead of the brain therapies business, will head the restorative therapies group.
Medtech In Politics: A Look At Republican And Democratic Party Platforms
The Republican presidential platform bashes the US FDA for "chilling and killing" development of new devices, pledging to restore the agency as a leader in medical innovation, while the Democratic Party platform focuses on supporting public health options, including higher funding levels to fight the Zika virus. The two platforms also diverge on tax and trade policy.
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.